157 related articles for article (PubMed ID: 35688904)
1. Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis.
Shan W; Wu G; Huang Y; Zeng H; Xia W; Lin Z; Xu B
Ann Hematol; 2022 Aug; 101(8):1741-1753. PubMed ID: 35688904
[TBL] [Abstract][Full Text] [Related]
2. Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials.
Wang Y; Ma Z; An Z; Zhang Y; Feng X; Yu X
Cancer Med; 2023 Feb; 12(3):2227-2237. PubMed ID: 35986570
[TBL] [Abstract][Full Text] [Related]
3. Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis.
Gao S; Zhang M; Wu K; Zhu J; He Z; Li J; Chen C; Qiu K; Yu X; Wu J
Expert Opin Drug Saf; 2020 May; 19(5):617-623. PubMed ID: 31955620
[No Abstract] [Full Text] [Related]
4. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis.
Zhang Y; Ma Z; Wang Y; Feng X; An Z
Expert Rev Clin Pharmacol; 2023; 16(9):855-863. PubMed ID: 37489925
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis.
Jfri A; Meltzer R; Mostaghimi A; LeBoeuf N; Guggina L
JAMA Oncol; 2022 Oct; 8(11):1635-43. PubMed ID: 36227613
[TBL] [Abstract][Full Text] [Related]
7. Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Martel S; Bruzzone M; Ceppi M; Maurer C; Ponde NF; Ferreira AR; Viglietti G; Del Mastro L; Prady C; de Azambuja E; Lambertini M
Cancer Treat Rev; 2018 Jan; 62():123-132. PubMed ID: 29108713
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract][Full Text] [Related]
9. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
Raphael J; Desautels D; Pritchard KI; Petkova E; Shah PS
Eur J Cancer; 2018 Mar; 91():38-46. PubMed ID: 29331750
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review.
Wen Y; Meng L; Zhang X; Gao Q
Expert Rev Hematol; 2022 Sep; 15(9):849-856. PubMed ID: 35920616
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
12. Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials.
Bowling GC; Swargaloganathan P; Heintz C; Madan RA; Eldhose B; Dobi A; Chesnut GT
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835597
[TBL] [Abstract][Full Text] [Related]
13. PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.
Sapon-Cousineau V; Sapon-Cousineau S; Assouline S
Curr Treat Options Oncol; 2020 Apr; 21(6):51. PubMed ID: 32356174
[TBL] [Abstract][Full Text] [Related]
14. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
15. Phosphoinositide 3-kinase inhibitors in lymphoma.
Curran E; Smith SM
Curr Opin Oncol; 2014 Sep; 26(5):469-75. PubMed ID: 25024054
[TBL] [Abstract][Full Text] [Related]
16. The role of PI3K inhibitors in the treatment of malignant lymphomas.
Berning P; Lenz G
Leuk Lymphoma; 2021 Mar; 62(3):517-527. PubMed ID: 33135516
[TBL] [Abstract][Full Text] [Related]
17. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.
Li X; Dai D; Chen B; Tang H; Xie X; Wei W
PLoS One; 2018; 13(2):e0192464. PubMed ID: 29408858
[TBL] [Abstract][Full Text] [Related]
19. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
20. PI3K Inhibitors and Adverse Events: Optimizing Patient Care for the Treatment of Advanced Breast Cancer.
Donahue S; Santos Fulgencio G
Clin J Oncol Nurs; 2020 Dec; 24(6):673-680. PubMed ID: 33216054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
